… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
… ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. … of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform. Dr. Beal’s decades of …
… against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition … stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR’s intellectual …
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7 th Annual Genetic … am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ™ EONs are …
… title: Harnessing chemical modifications to improve ADAR potency and unlock Axiomer broad applicability Presenter: Lenka van Sint Fiet, PhD, … effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design …